JP2008501722A - Ｃ５ａ拮抗剤としてのピリジン誘導体 - Google Patents

Ｃ５ａ拮抗剤としてのピリジン誘導体 Download PDF

Info

Publication number
JP2008501722A
JP2008501722A JP2007519572A JP2007519572A JP2008501722A JP 2008501722 A JP2008501722 A JP 2008501722A JP 2007519572 A JP2007519572 A JP 2007519572A JP 2007519572 A JP2007519572 A JP 2007519572A JP 2008501722 A JP2008501722 A JP 2008501722A
Authority
JP
Japan
Prior art keywords
alkyl
tetrahydroquinoline
isopropylphenyl
carboxamide
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501722A5 (cg-RX-API-DMAC7.html
Inventor
ラチャンス，ニコラス
ロイ，パトリック
レブランク，イベス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of JP2008501722A publication Critical patent/JP2008501722A/ja
Publication of JP2008501722A5 publication Critical patent/JP2008501722A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2007519572A 2004-06-10 2005-06-07 Ｃ５ａ拮抗剤としてのピリジン誘導体 Pending JP2008501722A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57850004P 2004-06-10 2004-06-10
PCT/CA2005/000891 WO2005121095A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists

Publications (2)

Publication Number Publication Date
JP2008501722A true JP2008501722A (ja) 2008-01-24
JP2008501722A5 JP2008501722A5 (cg-RX-API-DMAC7.html) 2008-05-08

Family

ID=35502992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519572A Pending JP2008501722A (ja) 2004-06-10 2005-06-07 Ｃ５ａ拮抗剤としてのピリジン誘導体

Country Status (7)

Country Link
US (2) US7429666B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758865A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008501722A (cg-RX-API-DMAC7.html)
CN (1) CN1968931A (cg-RX-API-DMAC7.html)
AU (1) AU2005251839A1 (cg-RX-API-DMAC7.html)
CA (1) CA2568673A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005121095A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
NZ570844A (en) * 2006-02-28 2011-11-25 Helicon Therapeutics Inc Therapeutic piperazines as PDE4 inhibitors
CN101553244B (zh) * 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
KR20090074219A (ko) * 2006-10-04 2009-07-06 쉐링 코포레이션 트롬빈 수용체 길항제로서의 비사이클릭 및 트리사이클릭 유도체
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
CN108508130B (zh) * 2018-04-11 2020-01-17 国家烟草质量监督检验中心 一种超高效合相色谱-串联质谱技术拆分、测定手性农药甲霜灵和烯酰吗啉对映体的方法
US20240293380A1 (en) * 2021-06-16 2024-09-05 The Cleveland Clinic Foundation Protease inhibitors and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082826A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
WO2003082828A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP1318140B1 (en) * 2000-09-14 2011-05-18 Mitsubishi Tanabe Pharma Corporation Novel amide derivatives and medicinal use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1318140B1 (en) * 2000-09-14 2011-05-18 Mitsubishi Tanabe Pharma Corporation Novel amide derivatives and medicinal use thereof
WO2003082826A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
WO2003082828A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components

Also Published As

Publication number Publication date
EP1758865A1 (en) 2007-03-07
WO2005121095A1 (en) 2005-12-22
US20050277644A1 (en) 2005-12-15
CN1968931A (zh) 2007-05-23
EP1758865A4 (en) 2010-07-21
US20090023774A1 (en) 2009-01-22
CA2568673A1 (en) 2005-12-22
US7429666B2 (en) 2008-09-30
AU2005251839A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
US12221441B2 (en) Plasma kallikrein inhibitors and uses thereof
US20090023774A1 (en) Pyridine analogs as C5A antagonists
TWI282335B (en) A61k 31/437 200601 a i vhtw a61p 31/04 200601 a i vhtw
JP6382403B2 (ja) Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
CN105814045B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
AU2003223755B2 (en) Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity
JP2978850B2 (ja) ２−アミノベンズアゼピン誘導体
CA2923269C (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
US20090227571A1 (en) Androgen Receptor Modulator Compounds and Methods
JP2011526295A (ja) ５員および６員複素環化合物
JPH10509150A (ja) 酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ
JP2004509120A (ja) カスパーゼ阻害剤およびそれらの用途
US20160194321A1 (en) Pyrrolopyridine or pyrazolopyridine derivatives
TW201105667A (en) Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
JP2022504762A (ja) Ｌｒｒｋ２の野生型および変異型の分解誘導剤
EP2968233A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
JP2000501432A (ja) 新規インドール―２，３―ジオン―３―オキシム誘導体
JP2009507795A (ja) 化合物
US20100137276A1 (en) Compounds which potentiate ampa receptor and uses thereof in medicine
JP7041141B2 (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
JP7561285B2 (ja) 複素環置換の縮合γ－カルボリン誘導体、その製造方法、中間体及び使用
US20070099950A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
KR20140082643A (ko) 알파 2 아드레날린성 수용체들의 조절인자들로서 N-(이미다졸리딘-2-일리덴)-헤테로사이클로펜타[b]피리딘유도체들
TW200924772A (en) Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
US20040122218A1 (en) Pyrrolopyridine potassium channel openers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080318

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090828

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110802